ARHGAPs, or Rho GTPase activating proteins, are a family of proteins that regulate Rho GTPases, which are critical for cell signaling. Rho GTPases are molecular switches that control various cellular processes, including cytoskeletal dynamics, cell migration, and proliferation. They cycle between an active GTP-bound state and an inactive GDP-bound state. ARHGAP proteins facilitate the transition of Rho GTPases from their active to inactive form by increasing their intrinsic GTPase activity. This regulation is crucial for maintaining cellular homeostasis and responding to extracellular signals. Dysregulation of Rho GTPase signaling can lead to various diseases, including cancer, underscoring the importance of ARHGAPs in cell biology.
Targeting ARHGAPs for disruption or inhibition has emerged as a potential strategy in diseases where Rho GTPase signaling is aberrant. Inhibiting specific ARHGAPs can modulate the activity of Rho GTPases, thereby altering cellular behaviors that contribute to disease progression. For example, in cancer, targeting ARHGAPs could disrupt tumor cell migration and invasion. However, this approach requires careful consideration of the specific ARHGAP and tissue context, as Rho GTPases play diverse roles in different cell types. Additionally, targeting ARHGAPs poses challenges in achieving specificity and avoiding unintended effects on normal cellular functions.
| 製品名 | CAS # | カタログ # | 数量 | 価格 | 引用文献 | レーティング |
|---|---|---|---|---|---|---|
Fasudil, Monohydrochloride Salt | 105628-07-7 | sc-203418 sc-203418A sc-203418B sc-203418C sc-203418D sc-203418E sc-203418F | 10 mg 50 mg 250 mg 1 g 2 g 5 g 10 g | $18.00 $32.00 $85.00 $165.00 $248.00 $486.00 $910.00 | 5 | |
ROCK阻害剤は、経路フィードバックを減少させることによりARHGAP活性を安定化させる可能性がある。 | ||||||
H-1152 dihydrochloride | 451462-58-1 | sc-203592 sc-203592A | 1 mg 5 mg | $102.00 $357.00 | 7 | |
ARHGAP39のRho GTPaseに対する制御作用に影響を与える可能性のあるもう一つのRhoキナーゼ阻害剤。 | ||||||
EHT 1864 | 754240-09-0 | sc-361175 sc-361175A | 10 mg 50 mg | $209.00 $872.00 | 12 | |
Rac1阻害剤は、不活性なRac1を安定化させることで、ARHGAPを介したシグナル伝達を減少させることができる。 | ||||||
PHA-848125 | 802539-81-7 | sc-364581 sc-364581A | 5 mg 10 mg | $304.00 $555.00 | ||
GEFであるTrioを阻害し、ARHGAPを介したGTPase活性を修飾する可能性がある。 | ||||||
Rhosin | 1173671-63-0 | sc-507401 | 25 mg | $555.00 | ||
RhoAとGEFの結合を選択的に阻害し、ARHGAPの制御作用を調節している可能性がある。 | ||||||
Interleukin-1 Receptor-Associated-Kinase-1/4 Inhibitor 抑制剤 | 509093-47-4 | sc-204013 | 5 mg | $160.00 | 2 | |
Cdc42活性特異的阻害剤は、ARHGAPの調節作用を調整するかもしれない。 | ||||||
ZCL278 | 587841-73-4 | sc-507369 | 10 mg | $115.00 | ||
Cdc42阻害剤は、ARHGAPによって制御される下流のプロセスに影響を与える可能性がある。 | ||||||
PAC 1 | 315183-21-2 | sc-203174 sc-203174A | 10 mg 50 mg | $129.00 $525.00 | 1 | |
シトヘシンを阻害し、間接的にARHGAP活性に影響を与える可能性がある。 | ||||||
RKI-1447 | 1342278-01-6 | sc-472590 | 1 mg | $330.00 | ||
JMYとRhoAの相互作用を阻害し、Rho GTPase経路におけるARHGAPの活性に間接的に影響を与える。 | ||||||